콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

PZ0416

Sigma-Aldrich

PF-05480090

≥98% (HPLC)

동의어(들):

(2R,3S)-2-(4-(But-2-ynyloxy)phenylsulfonamido)-N,3-dihydroxybutanamide, (2R,3S)-2-({[4-(2-Butynyloxy)phenyl]sulfonyl}amino)-N,3-dihydroxybutanamide, (2R,3S)-2-[[[4-(2-Butyn-1-yloxy)phenyl]sulfonyl]amino]-N,3-dihydroxybutanamide, PF 05480090, PF 548, PF 5480090, PF-548, PF-5480090, PF05480090, PF548, PF5480090, TMI 002, TMI 2, TMI-002, TMI-2, TMI002, TMI2, WAY 180022, WAY 18022, WAY-180022, WAY-18022, WAY180022, WAY18022

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C14H18N2O6S
CAS Number:
Molecular Weight:
342.37
UNSPSC 코드:
12352200
NACRES:
NA.77

Quality Level

분석

≥98% (HPLC)

형태

powder

색상

white to beige

solubility

DMSO: 2 mg/mL, clear

저장 온도

2-8°C

SMILES string

C[C@@H]([C@H](C(NO)=O)NS(=O)(C1=CC=C(C=C1)OCC#CC)=O)O

생화학적/생리학적 작용

PF-05480090 (PF-5480090; TMI-2) is an orally active, potent TACE (ADAM17) inhibitor (IC50 = 2 nM) with good selectivity over ADAM10 (IC50 = 1.09 μM), MMP-1/7 (IC50 = 2.47/0.96 μM) and MMP-8/9/13/14 (IC50 =35/ 777/96/582 nM). TMI-2 inhibits LPS-induced TNF production in cultrues (RAW/THP-1 IC50 = 200/430 nM), ex vivo (human whole blood IC50 = 1 μM) and in vivo (ED50 = 3 mg/kg; TMI-2 p.o. 1 hr prior to 40 ng LPS/mouse i.v.). TMI-2 is efficacious in a rat model of adjuvant-induced arthritis (AIA; 30 and 100 mg/kg p.o. b.i.d.) and a murine model of collagen-induced arthritis (CIA; 100 mg/kg p.o. b.i.d.).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Amy W Ku et al.
eLife, 5 (2016-12-09)
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that
Yuhua Zhang et al.
International immunopharmacology, 4(14), 1845-1857 (2004-11-09)
TNF-alpha converting enzyme (TACE) is a validated therapeutic target for the development of oral tumor necrosis factor-alpha (TNF-alpha) inhibitors. Here we report the pre-clinical results and characterization of a selective and potent TACE inhibitor, (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide (TMI-2), in various in
Marta Stolarczyk et al.
American journal of physiology. Lung cellular and molecular physiology, 314(4), L555-L568 (2018-01-20)
The EGF receptor (EGFR)/a disintegrin and metalloproteinase 17 (ADAM17) signaling pathway mediates the shedding of growth factors and secretion of cytokines and is involved in chronic inflammation and tissue remodeling. Since these are hallmarks of cystic fibrosis (CF) lung disease
Mengcheng Shen et al.
Circulation research, 123(3), 372-388 (2018-06-23)
ADAM17 (a disintegrin and metalloproteinase-17) is a membrane-bound enzyme that regulates bioavailability of multiple transmembrane proteins by proteolytic processing. ADAM17 has been linked to several pathologies, but its role in thoracic aortic aneurysm (TAA) has not been determined. The objective
Marta Stolarczyk et al.
Physiological reports, 4(16) (2016-08-27)
Aberrant activity of a disintegrin and metalloprotease 17 (ADAM17), also known as TACE, and epidermal growth factor receptor (EGFR) has been suggested to contribute to chronic obstructive pulmonary disease (COPD) development and progression. The aim of this study was to

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.